Roswellness Radio: Provenge Vaccine For Prostate Cancer

PrintE-mail
Sunday, June 12, 2011

Dr. Roberto Pili, Chief of the Genitourinary Section and Co-leader of the Genitourinary Program at RPCI, talks about Provenge, the first FDA-approved vaccine for the treatment of cancer. Joined by prostate-cancer survivor Russell Even, he talks about this drug, also known as sipuleucel-T, a new treatment option for some men with advanced prostate cancer.

You are missing some Flash content that should appear here! Perhaps your browser cannot display it, or maybe it did not initialize correctly.

Roberto Pili, MD in his lab

Cancer Can't Win

More patients are being diagnosed with cancer every day.

Here at Roswell Park Cancer Institute, we must continue to do what we do best – to understand, prevent and cure cancer. Because if we don’t, cancer wins. And Cancer Can’t Win.

  • With more than 3,000 scientific, academic and medical minds – Cancer Can’t Win.
  • When we are leading an advanced genetic program and creating next generation cancer vaccines to prevent it – Cancer Can’t Win.
  • When we are starting 13 new companies to advance our discoveries and share them with the world – Cancer Can’t Win.

Learn more about why Cancer Can’t Win

close